DrugMapper


InChI Key	HWGQMRYQVZSGDQ-HZPDHXFCSA-N
Smile	Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1
InChI	InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1

Action	Mechanism of Action	Reference
INHIBITOR	Poly [ADP-ribose] polymerase-1 inhibitor	PubMed

	Primary Target
poly(ADP-ribose) polymerase 1
poly(ADP-ribose) polymerase 2

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Transferase	3-3	1-7	-	1-1	91

Mesh Heading	Maximum Phase	Mesh ID	Reference
Neoplasms	4	D009369	ClinicalTrials
Prostatic Neoplasms, Castration-Resistant	3	D064129	ClinicalTrials
Ovarian Neoplasms	3	D010051	ClinicalTrials
Breast Neoplasms	3	D001943	ClinicalTrials
Breast Neoplasms	3	D001943	ClinicalTrials
Small Cell Lung Carcinoma	2	D055752	ClinicalTrials
Triple Negative Breast Neoplasms	2	D064726	ClinicalTrials
Prostatic Neoplasms	2	D011471	ClinicalTrials
Hemangiosarcoma	2	D006394	ClinicalTrials
Urinary Bladder Neoplasms	2	D001749	ClinicalTrials
Carcinoma, Squamous Cell	2	D002294	ClinicalTrials
Carcinoma, Non-Small-Cell Lung	2	D002289	ClinicalTrials
Hereditary Breast and Ovarian Cancer Syndrome	2	D061325	ClinicalTrials
Prostatic Neoplasms	2	D011471	ClinicalTrials
Carcinoma, Renal Cell	2	D002292	ClinicalTrials
Endometrial Neoplasms	2	D016889	ClinicalTrials
Glioblastoma	2	D005909	ClinicalTrials
Leukemia, Myeloid, Acute	1	D015470	ClinicalTrials
Pancreatic Neoplasms	1	D010190	ClinicalTrials
Leukemia	1	D007938	ClinicalTrials

Level 3

Level 4

Level 5

Level 6

Indication

Mechanism of Action

Primary Target

Target Level

Salt

TALAZOPARIB


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70